Iododeoxyuridine uptake in proliferating smooth muscle cells in vitro. 2007

Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
Department of Radiology, Indiana University Medical Center, Indianapolis, IN 47405, USA.

OBJECTIVE Iododeoxyuridine (IUdR) is a halogenated pyrimidine recognized as the thymidine substitute in DNA. When labeled with iodine 125, IUdR can be used as a carrier to incorporate the isotope into DNA and target the dividing cells. The purpose of this study was to assess the maximum uptake of IUdR by proliferating smooth muscle cells (SMCs) in vitro to determine the optimal concentration to be administered in an in vivo experiment. The long-term goal is to use radioactive IUdR to inhibit SMC proliferation and recurrent stenosis of arteries after balloon angioplasty in vivo. METHODS Porcine vascular SMCs were cultured in 5% fetal bovine serum medium and stimulated to proliferate by adding a medium containing 10% fetal bovine serum and insulin. IUdR was added to the proliferating SMCs at concentrations of 5, 10, 20, 30, and 40 micro mol/L on days 1, 3, 5, and 7 of incubation. One group of cells--the control group--did not receive IUdR. The SMCs were harvested and double-stained with an anti-IUdR antibody and propidium iodide, and fluorescence-activated cell scanning was performed to determine the ratio of IUdR-labeled cells to the total cell population for each IUdR concentration and at each time point. The data were measured three times at each time point. The doubling times, growth curve, and cell density of the proliferating SMCs were investigated by using the Coulter particle counter and digital microscopy. RESULTS The percentage of proliferating SMCs that showed IUdR uptake increased from 1 to 5 days incubation with all concentrations of IUdR; the incorporation rate reached a peak value at day 5 and then decreased by day 7. IUdR uptake on day 5 was higher with concentrations of 10 and 20 micro mol/L. When compared with that of the control group, the doubling times increased with an increase in IUdR concentration, whereas the proliferating cell number and density decreased significantly by days 5 (P < .05) and 7 (P < .01). CONCLUSIONS IUdR uptake peaked on day 5, and the optimal concentration of IUdR for in vitro uptake in proliferating SMCs was 10-20 micro mol/L. IUdR inhibited the proliferation of the SMCs, and the inhibitory effect was related to the concentration.

UI MeSH Term Description Entries
D007065 Idoxuridine An analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent. 5-Iodo-2'-deoxyuridine,IUdR,Iododeoxyuridine,5-Iododeoxyuridine,Allergan 211,Herplex Liquifilm,Idoxuridine, 123I-Labeled,Idoxuridine, 125I-Labeled,Idoxuridine, 131I-Labeled,Idoxuridine, 3H-Labeled,Idoxuridine, Radical Ion (+1),Idoxuridine, Radical Ion (1-),Kerecide,NSC-39661,Oftan-IDU,SK&F-14287,Stoxil,123I-Labeled Idoxuridine,125I-Labeled Idoxuridine,131I-Labeled Idoxuridine,3H-Labeled Idoxuridine,5 Iodo 2' deoxyuridine,5 Iododeoxyuridine,Idoxuridine, 123I Labeled,Idoxuridine, 125I Labeled,Idoxuridine, 131I Labeled,Idoxuridine, 3H Labeled,Liquifilm, Herplex,NSC 39661,NSC39661,Oftan IDU,OftanIDU
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D006083 Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts. Graft Restenosis, Vascular,Vascular Graft Occlusion,Vascular Graft Restenosis,Graft Restenoses, Vascular,Occlusion, Vascular Graft,Restenosis, Vascular Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D019384 Nucleic Acid Synthesis Inhibitors Compounds that inhibit cell production of DNA or RNA. DNA Polymerase Inhibitor,DNA Synthesis Inhibitor,DNA Synthesis Inhibitors,Nucleic Acid Synthesis Inhibitor,RNA Synthesis Inhibitor,RNA Synthesis Inhibitors,DNA Polymerase Inhibitors,Inhibitors, DNA Synthesis,Inhibitors, Nucleic Acid Synthesis,Inhibitors, RNA Synthesis,Inhibitor, DNA Polymerase,Inhibitor, DNA Synthesis,Inhibitor, RNA Synthesis,Inhibitors, DNA Polymerase,Polymerase Inhibitor, DNA,Polymerase Inhibitors, DNA,Synthesis Inhibitor, DNA,Synthesis Inhibitor, RNA,Synthesis Inhibitors, DNA,Synthesis Inhibitors, RNA
D032389 Myocytes, Smooth Muscle Non-striated, elongated, spindle-shaped cells found lining the digestive tract, uterus, and blood vessels. They are derived from specialized myoblasts (MYOBLASTS, SMOOTH MUSCLE). Smooth Muscle Cells,Cell, Smooth Muscle,Cells, Smooth Muscle,Myocyte, Smooth Muscle,Smooth Muscle Cell,Smooth Muscle Myocyte,Smooth Muscle Myocytes

Related Publications

Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
December 1997, Atherosclerosis,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
February 1989, American journal of hypertension,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
December 1998, The American journal of physiology,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
April 2009, American journal of physiology. Heart and circulatory physiology,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
September 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
November 2015, Pathology international,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
November 2000, Electrophoresis,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
June 1978, Agents and actions,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
February 1990, Journal of cellular physiology,
Yonghua Xu, and Mandar R Jagtap, and Tam Garland, and Jun Ying, and Ronald C McGarry, and Marc S Mendonca, and Gordon McLennan
May 2004, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Copied contents to your clipboard!